Peptide vaccine with glucopyranosyl lipid A-stable oil-in-water emulsion for patients with resected melanoma
Eric P Grewal, Courtney L Erskine, Wendy K Nevala, Jacob B Allred, Carrie A Strand, Lisa A Kottschade, Robert R McWilliams, Roxana S Dronca, Adam J Yakovich, Svetomir N Markovic, Matthew S Block, Eric P Grewal, Courtney L Erskine, Wendy K Nevala, Jacob B Allred, Carrie A Strand, Lisa A Kottschade, Robert R McWilliams, Roxana S Dronca, Adam J Yakovich, Svetomir N Markovic, Matthew S Block
Abstract
Aim: We tested the safety and immunogenicity of a novel vaccine in patients with resected high-risk melanoma. Patients & methods: HLA-A2-positive patients with resected Stage II-IV melanoma were randomized to receive up to three vaccinations of melanoma-associated peptide (MART-1a) combined with a stable oil-in-water emulsion (SE) either with the Toll-like receptor 4 agonist glucopyranosyl lipid A (GLA-SE-Schedule 1) or alone (SE-Schedule 2). Safety and immunogenicity of the vaccines were monitored. Results: A total of 23 patients were registered. No treatment-related grade 3 or higher adverse events were observed. Increases in MART-1a-specific T cells were seen in 70 and 63% of Schedule 1 and Schedule 2 patients, respectively. Conclusion: Both vaccine schedules were well-tolerated and resulted in an increase in MART-1a-specific T cells. Clinical Trial registration: NCT02320305 (ClinicalTrials.gov).
Keywords: MART-1; Phase I; T cell; glucopyranosyl lipid A; immunotherapy; melanoma; peptide; vaccine.
Source: PubMed